Bo Ying, Abogen founder (Xi'an Jiaotong-Liverpool University)
China’s top mRNA contender is ready to go. And SoftBank just led a cash infusion pushing it over the $1B line
With Moderna and BioNTech offering a model — in the US and Europe, respectively — for how mRNA biotechs can enjoy a meteoric rise to profit and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
